SynthesisFrontiers in immunology2025
The association between ankylosing spondylitis and the risk of venous thromboembolism: a meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multicenter explainable machine learning analysis of autoimmune disease comorbidity in ankylosing spondylitis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune diseases are frequently associated with an increased risk of venous thromboembolism (VTE). However, the relationship between ankylosing spondylitis (AS) and VTE remains unclear. This meta-analysis was conducted to evaluate the association between AS and VTE risk, with the aim of providing evidence-based insights to guide clinical practice. Method: We searched PubMed, Embase, the Cochrane Library, and Web of Science for studies published from database inception until June 2025 that compared VTE risk in patients with AS. Two researchers independently screened the literature based on predefined inclusion and exclusion criteria. The risk of bias in included studies was assessed using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to estimate effect sizes. Subgroup analyses were performed according to the type of thrombosis event. Sensitivity analysis was conducted by sequentially excluding each study. Publication bias was preliminarily assessed using funnel plots. The overall quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. All analyses were performed using RevMan 5.3 software. The study protocol was registered retrospectively in PROSPERO (Registration number: CRD420251107387). Results: Six studies involving 601,585 patients were included. The meta-analysis indicated that AS was associated with a significantly higher risk of VTE (HR = 1.47, 95%CI(1.22,1.77), P < 0.0001; evidence quality: Very low). Subgroup analyses revealed that AS was significantly associated with an increased risk of overall VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE) (VTE: HR = 1.57, 95%CI(1.26, 1.96), P < 0.0001; DVT: HR = 1.62, 95%CI(1.16, 2.26), P = 0.005; PE: HR = 1.24, 95%CI(1.06, 1.45), P = 0.008). Conclusion: Current evidence indicates that AS may elevate the risk of VTE. Further mechanistic studies are needed to better interpret these findings derived from observational data. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251107387.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.